益气固本汤联合噻托溴铵治疗慢性阻塞性肺疾病稳定期临床研究  

Clinical Study on Yiqi Guben Tang Combined with Tiotropium Bromide for Chronic Obstructive Pulmonary Disease at Stable Stage

作　　者：魏琳莹 汪志平[1] WEI Linying;WANG Zhiping

机构地区：[1]常山县人民医院呼吸内科,浙江常山324200

出　　处：《新中医》2021年第20期70-74,共5页New Chinese Medicine

摘　　要：目的:观察益气固本汤联合噻托溴铵治疗慢性阻塞性肺疾病(COPD)稳定期患者临床疗效及对肺功能、缺血修饰白蛋白(IMA)、淀粉样蛋白A (SAA)水平的影响。方法:选取COPD稳定期患者120例,随机分为观察组和对照组各60例。对照组给以噻托溴铵粉雾剂治疗,观察组在对照组的基础上加用益气固本汤治疗。观察比较2组临床疗效,2组治疗前后中医证候积分,肺功能[第1秒用力呼气容积(FEV_(1))、第1秒用力呼气容积占预计值百分比(FEV_(1)%预计值)、FEV_(1)与用力肺活量的比值(FEV_(1)/FVC)],血清IMA、SAA水平变化。结果:观察组总有效率为93.33%,对照组为75.00%,2组比较,差异有统计学意义(P<0.05)。治疗前,2组中医证候积分比较,差异无统计学意义(P>0.05);治疗后,2组咳嗽、咳痰、胸痛、呼吸困难、皮肤晦暗无光泽、口干口渴、疲倦乏力及盗汗自汗评分均较治疗前降低(P<0.05),且观察组上述各项症状评分均低于对照组(P<0.05)。治疗前,2组FEV_(1)、EFV1%预计值及FEV_(1)/FVC水平比较,差异无统计学意义(P>0.05);治疗后,2组上述各项肺功能指标均较治疗前升高(P<0.05),且观察组各指标均高于对照组(P<0.05)。治疗前,2组IMA、SAA水平比较,差异无统计学意义(P>0.05);治疗后,2组IMA、SAA水平均较治疗前降低(P<0.05),且观察组IMA、SAA水平低于对照组(P<0.05)。治疗过程中2组均未发生严重不良反应。结论:益气固本汤联合噻托溴铵粉雾剂治疗COPD稳定期患者疗效显著,能显著改善临床症状和肺功能,有效调节SAA、IMA水平,且安全性良好。Objective:To observe the clinical effect of Yiqi Guben tang combined with tiotropium bromide for patients with chronic obstructive pulmonary disease(COPD) at stable stage, and its effect on the lung function and levels of ischemia modified albumin(IMA) and serum amyloid A(SAA). Methods: A total of 120 cases of COPD patients at stable stage were selected and randomly divided into the observation group and the control group,60 cases in each group. The control group was treated with tiotropium bromide inhalation powder,and the observation group was additionally treated with Yiqi Guben tang based on the treatment of the control group. The clinical effect was observed and compared between the two groups.Before and after treatment,changes in Chinese medicine syndrome scores,forced expiratory volume in one second(FEV_(1)),of the lung function,forced expiratory volume in one second as a percentage of estimated value(FEV_(1)% pred),forced expiratory volume in one second to forced vital capacity(FEV_(1)/FVC),and levels of IMA and SAA in serum were observed and compared between the two groups. Results:The total effective rate was 93.33% in the observation group,and 75.00% in the control group,the difference being significant(P<0.05). Before treatment,there was no significant difference being found in the comparison of Chinese medicine symptom scores between the two groups(P>0.05). After treatment, scores of cough,expectoration,chest pain,dyspnea,dark and lusterless complexion,dry mouth and thirsty,fatigue and lack of strength,as well as night sweating and spontaneous sweating in the two groups were decreased when compared with those before treatment(P<0.05), and the scores above in the observation group were lower than those in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparisons of levels of FEV_(1),FEV_(1)%pred,FEV_(1)/FVC between the two groups(P>0.05);after treatment, the indexes above in the two groups were increased when compared with those before treatment(P<0.

关 键 词：慢性阻塞性肺疾病稳定期 益气固本汤 噻托溴铵 肺功能 缺血修饰清蛋白 淀粉样蛋白A 

分 类 号：R563[医药卫生—呼吸系统]